Advertisement

pp 1-27 | Cite as

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

  • Dennis McKenna
  • Jordi Riba
Chapter
Part of the Current Topics in Behavioral Neurosciences book series

Abstract

New World indigenous peoples are noted for their sophisticated use of psychedelic plants in shamanic and ethnomedical practices. The use of psychedelic plant preparations among New World tribes is far more prevalent than in the Old World. Yet, although these preparations are botanically diverse, almost all are chemically similar in that their active principles are tryptamine derivatives, either DMT or related constituents. Part 1 of this paper provides an ethnopharmacological overview of the major tryptamine-containing New World hallucinogens .

Keywords

Tryptamine derivatives Tryptamine Hallucinogen Hallucinogenic New World Shamanism Botany Chemistry Ethnopharmacology 

Literature Cited

  1. Borhegyi SF (1961) Miniature mushroom stones from Guatemala. Am Antiq 26:498–504CrossRefGoogle Scholar
  2. Cooper JM (1949) Stimulants and narcotics. In: Handbook of South American Indians, vol 5. Bureau of American Ethnology Bulletin # 143. Smithsonian Institution, WashingtonGoogle Scholar
  3. Dale GD (1991) The Santo Daime doctrine: an interview with Alex Polari de Alverga. Shaman’s Drum 22:30–41Google Scholar
  4. Daly JW, Witkop B (1971) Chemistry and pharmacology of frog venoms. In: Bücherl W, Buckley EE (eds) Venomous animals and their venoms, vol. II. Academic Press, LondonGoogle Scholar
  5. Davis W, Weil AT (1992a) Bufo alvarius: a potent hallucinogen of animal origin. J Ethnopharmacol 41:1–8Google Scholar
  6. Davis W, Weil AT (1992b) Identity of a new world psychoactive toad. Ancient Mesoamerica 3:51–59CrossRefGoogle Scholar
  7. Der Marderosian AH, Pinkley HV, Dobbins MF (1968) Native use and occurrence of N,N-dimethyltryptamine in the leaves of Banisterioposisrusbyana. Am J Pharm 140:137–147PubMedGoogle Scholar
  8. Emboden W (1979) Narcotic plants. Collier Books, New YorkGoogle Scholar
  9. Erowid.org (2001a) A list of the (186) known psilocybian mushrooms. https://www.erowid.org/plants/mushrooms/mushrooms_info12.shtml. Accessed 27 Dec 2014
  10. Erowid.org (2001b) Legal status of ayahuasca in Brazil. http://www.erowid.org/chemicals/ayahuasca/ayahuasca_law6.shtml. Accessed 29 Dec 2014
  11. Erowid.org (2006) UDV wins Supreme Court decision on preliminary injunction http://www.erowid.org/chemicals/ayahuasca/ayahuasca_law22.shtml. Accessed 29 Dec 2014
  12. Erowid.org (2012) Santo Daime wins court decision http://www.erowid.org/chemicals/ayahuasca/ayahuasca_law24.shtml. Accessed 29 Dec 2014
  13. Fish MS, Johnson NM, Horning EC (1955) Piptadenia alkaloids—indole bases of Piptadeniaperegrina (L.) Benth and related species. J Am Chem Soc 77:5892–5895CrossRefGoogle Scholar
  14. Gates B (1979) New names in Banisteriopsis and Diplopterys (Malpighiaceae) of the Guayana highland. Brittonia 31:108–109CrossRefGoogle Scholar
  15. Guzmán G, Allen JW, Garrtz J (2000) A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion. AnnalideiMuseocivico - Rovereto, Italia. 14:189–280 (in English)Google Scholar
  16. Guzmán G, Ramírez-Guillén F, Torres G (2004) The hallucinogenic species of Psilocybe (Fr.) P. Kumm (Agaricomycetideae) in Colombia, their Indian use, new records, and new species. Int J Med Mushrooms 6:83–93Google Scholar
  17. Heim R, Hofmann A (1958) Isolement de la Psilocybine à partir du Strophariacubensis Earle etd’autresespèces de champignons hallucinogènesmexicainsappartenant au genre Psilocybe. In: Extrait des Comptesrendus des séances de l’Académie des Sciences, t. 247:557–561Google Scholar
  18. Holmstedt B, Lindgren JE (1967) Chemical constituents and pharmacology of South American snuffs. In: Efron DH, Holmstedt B, Kline NS (eds) Ethnopharmacologic search for psychoactive drugs, U.S. Public Health Service Publication # 1645. U.S. Government Printing OfficeGoogle Scholar
  19. Kennedy AB (1982) Ecce Bufo: the toad in nature and in Olmec Iconography. Curr Anthropol 23:273–290CrossRefGoogle Scholar
  20. Luna LE (1984) The concept of plants as teachers among four mestizo shamans of Iquitos, northeastern Peru. J Ethnopharmacol 11:135–156PubMedCrossRefGoogle Scholar
  21. Macrae WD, Towers GH (1984a) Justiciapectoralis: a study of the basis for its use as a hallucinogenic snuff ingredient. J Ethnopharmacol 12:93–111PubMedCrossRefGoogle Scholar
  22. Macrae WD, Towers GH (1984b) An ethnopharmacological examination of Virolaelongata bark: a South American arrow poison. J Ethnopharmacol 12:75–92PubMedCrossRefGoogle Scholar
  23. McKenna DJ, Luna LE, Towers GH (1995) Biodynamic constituents in Ayahuasca admixture plants: an uninvestigated folk pharmacopoeia. In: von Reis S, Schultes RE (eds) Ethnobotany: evolution of a discipline. Dioscorides Press, PortlandGoogle Scholar
  24. McKenna DJ, Towers GH (1984) Biochemistry and pharmacology of tryptamine and ß-carboline derivatives: a minireview. J Psychoactive Drugs 16:347–358PubMedCrossRefGoogle Scholar
  25. McKenna DJ, Towers GH, Abbott FS (1984a) Monoamine oxidase inhibitors in South American hallucinogenic plants Pt. II: constituents of orally active Myristicaceous hallucinogens. J Ethnopharmacol 12:179–211PubMedCrossRefGoogle Scholar
  26. McKenna DJ, Towers GH, Abbott FS (1984b) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and ß-carboline constituents of Ayahuasca. J Ethnopharmacol 10:195–223PubMedCrossRefGoogle Scholar
  27. Naranjo P (1995) Archeology and psychoactive plants. In: von Reis S, Schultes RE (eds) Ethnobotany: evolution of a discipline. Dioscorides Press, PortlandGoogle Scholar
  28. Ott J (1998) Pharmahuasca, anahuasca, vinho de Jurema: human pharmacology of oral DMT + harmine. In: Müller-Ebeling C (ed) Special: psychoactivity. Yearbook for Ethnomedicine and the study of consciousness 6/7 (1997–1998). VWB, BerlinGoogle Scholar
  29. Ott J (2001) Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J Psychoactive Drugs 33:273–281PubMedCrossRefGoogle Scholar
  30. Pachter IJ, Zacharius DE, Ribeiro O (1959) Indole alkaloids of Acer saccharinum (the silver maple), Dictylomaincanescens, Piptadeniacolubrina, and Mimosa hostilis. J Org Chem 24:1285–1287CrossRefGoogle Scholar
  31. PInkley HV (1969) Plant admixtures to ayahuasca, the South American hallucinogenic drink. Lloydia 32:305–314PubMedGoogle Scholar
  32. Rivier L, Lindgren J (1972) Ayahuasca, the South American hallucinogenic drink: ethnobotanical and chemical investigations. Econ Bot 29:101–129CrossRefGoogle Scholar
  33. Schultes RE (1969) Virola as an orally administered hallucinogen. Harvard Bot Mus Leaflets 22:229–240Google Scholar
  34. Schultes RE (1970a) The New World Indians and their hallucinogenic plants. Morris Arboretum Bull 21:3–14Google Scholar
  35. Schultes RE (1970b) The plant kingdom and hallucinogens (Part III). Bull Narc XXII:25–53Google Scholar
  36. Schultes RE, Holmstedt B (1968) The vegetal ingredients of the Myristicaceous snuffs of the Northwest Amazon. Rhodora 70:113–160Google Scholar
  37. Schultes RE, Hofmann A (1981) The botany and chemistry of hallucinogens, 2nd edn. Charles C. Thomas Publishers, Springfield, IllGoogle Scholar
  38. Schultes RE, Hofmann A (2001) Plants of the gods: their sacred, healing, and hallucinogenic powers. Healing Arts Press, RandolphGoogle Scholar
  39. Smith TA (1977) Tryptamine and related compounds in plants. Phytochemistry 16:171–175CrossRefGoogle Scholar
  40. Torres CM (1995) Archeological evidence for the antiquity of psychoactive plant use in the central Andes. Ann Mus Civ Revoreto 11:291–326Google Scholar
  41. Torres CM, Repke DB (2006) Anadenanthera: visionary plant of ancient South America. Haworth Herbal Press, RoutledgeGoogle Scholar
  42. Torres CM, Repke DB, Chan K, McKenna D, Llagostera A, Schultes RE (1992) Botanical, chemical, and contextual analysis of archaeological snuff powders from San Pedro de Atacama, Northern Chile. Curr Anthropol 32:640–649CrossRefGoogle Scholar
  43. Vepsäläinen JJ, Auriola S, Tukiainen M, Ropponen N, Callaway JC (2005) Isolation and characterization of yuremamine, a new phytoindole. Planta Med 71:1053–1057PubMedCrossRefGoogle Scholar
  44. Wassén SH (1967) Anthropological survey of the use of South American snuffs. In: Efron DH, Holmstedt B, Kline NS (eds) Ethnopharmacologic search for psychoactive drugs, U.S. Public Health Service Publication # 1645. U.S. Government Printing OfficeGoogle Scholar
  45. Wassén SH (1964) Some general viewpoints in the study of native drugs especially from the West indies and South America. Ethnos 1–2:97–120CrossRefGoogle Scholar
  46. Wasson RG (1967) Fly agaric and man. In: Efron DH, Holmstedt B, Kline NS (eds) Ethnopharmacologic search for psychoactive drugs, U. S. Public Health Service Publication # 1645. U.S. Government Printing OfficeGoogle Scholar
  47. Wasson RG (1980) The wondrous mushroom: mycolatry in Mesoamerica. McGraw-Hill Book Company, New YorkGoogle Scholar
  48. Wasson RG, Wasson V (1957) Seeking the magic mushroom. Life Magazine May 13, 1957Google Scholar
  49. Weil AT, Davis W (1994) Bufo alvarius: a potent hallucinogen of animal origin. J Ethnopharmacol 41(1–2):1–8Google Scholar

References

  1. Bouso JC, Fábregas JM, Antonijoan RM, Rodríguez-Fornells A, Riba J (2013) Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharmacology (Berl) 230:415–424CrossRefGoogle Scholar
  2. Bouso JC, González D, Fondevila S, Cutchet M, Fernández X, Ribeiro Barbosa PC, Alcázar-Córcoles MÁ, Araújo WS, Barbanoj MJ, Fábregas JM, Riba J (2012) Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of ayahuasca: a longitudinal study. PloS One 7:e42421ADSPubMedCentralPubMedCrossRefGoogle Scholar
  3. Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, Ribeiro S, Sanches R, Crippa JA, Hallak JEC, de Araujo DB, Riba J (in press) Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur NeuropsychopharmacolGoogle Scholar
  4. Cavanna AE, Trimble MR (2006) The precuneus: a review of its functional anatomy and behavioural correlates. Brain 129:564–583PubMedCrossRefGoogle Scholar
  5. Cloninger CR, Svrakic DM, Przybeck TR (1993) A psychobiological model of temperament and character. Arch Gen Psychiatry 50:975–990PubMedCrossRefGoogle Scholar
  6. De Araujo DB, Ribeiro S, Cecchi GA, Carvalho FM, Sanchez TA, Pinto JP, de Martinis BS, Crippa JA, Hallak JEC, Santos AC (2012) Seeing with the eyes shut: neural basis of enhanced imagery following Ayahuasca ingestion. Hum Brain Mapp 33:2550–2560PubMedCrossRefGoogle Scholar
  7. Frankel PS, Cunningham KA (2002) The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain. Brain Res 958:251–260PubMedCrossRefGoogle Scholar
  8. Friston K (2005) A theory of cortical responses. Philos Trans R Soc Lond B Biol Sci 360:815–836PubMedCentralPubMedCrossRefGoogle Scholar
  9. Gewirtz JC, Chen AC, Terwilliger R, Duman RC, Marek GJ (2002) Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol Biochem Behav 73:317–326PubMedCrossRefGoogle Scholar
  10. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53:439–452PubMedCrossRefGoogle Scholar
  11. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Büll U, Sass H (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 20:565–581CrossRefGoogle Scholar
  12. Hermle L, Fünfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, Spitzer M (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32:976–991PubMedCrossRefGoogle Scholar
  13. McKenna DJ (2000) An unusual experience with “hoasca”: a lesson from the teacher. In: Ayahuasca reader, encounters with the Amazon’s sacred vine, pp 154–157. Synergetic Press, Santa FeGoogle Scholar
  14. Mesulam M (2008) Representation, inference, and transcendent encoding in neurocognitive networks of the human brain. Ann Neurol 64:367–378PubMedCrossRefGoogle Scholar
  15. Mesulam MM (2000) Behavioral neuroanatomy: large-scale networks, association cortex, frontal syndromes, the limbic system, and hemispheric specializations. In: Mesulam MM (ed) Principles of behavioral and cognitive neurology. Oxford University Press, New York, pp 1–120Google Scholar
  16. Metzner R (1999) Ayahuasca: hallucinogens, consciousness and the spirit of nature. Thunder’s Mouth Press, New YorkGoogle Scholar
  17. Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Errtizoe D, Sessa B, Papadopoulos A, Bolstridge M, Singh KD, Feilding A, Friston KJ, Nutt DJ (2013) Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci 33:15171–15183PubMedCrossRefGoogle Scholar
  18. Riba J, Anderer P, Jané F, Saletu B, Barbanoj MJ (2004) Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology 50:89–101PubMedCrossRefGoogle Scholar
  19. Riba J, Romero S, Grasa E, Mena E, Carrió I, Barbanoj MJ (2006) Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl) 186:93–98CrossRefGoogle Scholar
  20. Roland PE, Gulyás B (1994) Visual imagery and visual representation. Trends Neurosci 17:281–287; discussion 294–297Google Scholar
  21. Sakai K, Miyashita Y (1994) Visual imagery: an interaction between memory retrieval and focal attention. Trends Neurosci 17:287–289PubMedCrossRefGoogle Scholar
  22. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357–372PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Director of EthnopharmacologyHeffter Research InstituteSanta FeUSA
  2. 2.Human Neuropsychopharmacology GroupSant Pau Institute of Biomedical Research (IIB-Sant Pau)BarcelonaSpain
  3. 3.Department of Pharmacology and TherapeuticsUniversitat Autònoma de Barcelona (UAB)BarcelonaSpain

Personalised recommendations